Ocugen Stock Forecast – what can investors expect over the next 5 years?

Ocugen stock forecast

Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has primarily focused its research on developing a cure for blindness disease. In 2020, Ocugen shifted its efforts to distribute a COVID-19 vaccine with Indian partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri made it clear that the company strategises to disrupt the current COVID-19 vaccine market with Covaxin.…

Sorrento Therapeutics (NASDAQ:SRNE) stock gains bullish momentum

SRNE stock

Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of Wallstreet after the company obtained authorisation to commence Phase 2 trials for its COVID-19 experimental treatment COVI-DROPS. COVIDROPS is a intranasal formulation of Sorrento’s COVI-AMG™ neutralizing antibody that aims to boost immunity by blocking the infection and spread of the virus.…

Novavax stock forecast (NASDAQ: NVAX) – are investors buying now?

Novavax, Inc.(NASDAQ: NVAX) has seen an incredible year in stock price growth, increasing 307% over the past 12 months. The companies COVID-19 vaccine saw the market rally behind NVAX, posting a 52 week high in February of $331.68. The company announced yesterday that their COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and a 90.4% efficacy overall in the Phase 3 trial.…

Vaxart stock (NASDAQ: VXRT) surges after analyst sees 105% upside

Vaxart Inc (NASDAQ: VXRT) stock has seen a recent spike in investor confidence, gaining 23.81% over the past week. Vaxart has developed an oral vaccine for COVID-19 which has vastly differentiated itself from the competition. A recent study by Quadrant Strategies has shown that one third of people refusing to be vaccinated for COVID-19, would take an oral vaccine as an alternative to an injection.…

BNGO stock forecast for 2021 and beyond

BNGO stock forecast 2021

BioNano Genomics Inc (NASDAQ: BNGO) has had a remarkable year of trading, gaining over 979% over the past two months. The company operates in the analytical instruments field, in particular cytogenomics. Simply put, this is the detection of genetic disorders by analyzing the variances in chromosomes.…

Analysts maintain buy rating on SRNE stock

UVXY ETF

Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of investors as analysts remain confident in the companies 12 month outlook. The stock has performed well as of late, posting a 29% gain over the past month of trading. Furthermore, the average 12 month price target amongst Wallstreet analysts is $29.67 a share.…

iBio’s stock forecast for 2021 and beyond

iBio inc. (NYSE:IBIO) rose to popularity amongst the investor community as they announced their intentions to develop a COVID-19 vaccine. The stock is currently trading 586% higher since the beginning of 2020. However since July, iBio stock has been on a downward slope which has since found a new equilibrium at $2.…